FrancophonIA/ELRC3.0 huggingface dataset:
English: Hold a pad firmly over the injection site on your outstretched arm for about 2 minutes.
Slovenian: Držite roko iztegnjeno in na mestu injiciranja še približno dve minuti pritiskajte blazinico.
English: Now that the solution has been transferred into the syringe, firmly hold on to the barrel of the syringe (keeping the syringe plunger facing down) and disconnect the transparent Mix2Vial adapter from the syringe by unscrewing counter clockwise.
Slovenian: Sedaj ko je raztopina v injekcijski brizgi, trdno primite injekcijsko brizgo (bat injekcijske brizge naj gleda navzdol) in odstranite prozoren Mix2Vial adapter z injekcijske brizge z odvijanjem v nasprotni smeri urinih kazalcev.
English: Filtering is achieved by using the Mix2Vial adapter.
Slovenian: Pri filtriranju je treba uporabiti adapter Mix2Vial.
English: Only the provided administration sets can be used because treatment failure can occur as a consequence of human recombinant coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.
Slovenian: Za rekonstitucijo in injiciranje zdravila se sme uporabiti samo priloženi pribor Če se uporabi drug pribor, je lahko zdravljenje zaradi adsorpcije humanega rekombinantnega koagulacijskega faktorja VIII na notranje stene nekaterih priborov za infundiranje neuspešno.
English: Similar to RODIN/Pednet, the UKHCDO study found a significant increased risk of inhibitors (all and high titre) for Kogenate FS/Helixate NexGen (2nd generation rFVIII) compared to Advate (3rd generation rFVIII).
Slovenian: V študiji UKHCDO so enako kot v študiji RODIN/Pednet ugotovili znatno povečanje tveganja za zaviralce (vsi titri in visoki titri) pri zdravilih Kogenate FS/Helixate NexGen (rFVIII 2. generacije) v
English: When infused into a haemophilic patient, factor VIII binds to vWF in the patient's circulation.
Slovenian: Po infundiranju bolniku s hemofilijo se faktor VIII v krvnem obtoku veže na vWF.
English: Common may affect up to 1 in 10 users):
Slovenian: Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
English: Helixate NexGen powder should only be reconstituted with the supplied solvent (2.5 mL (for 250 IU, 500 IU and 1000 IU) or 5 mL (for 2000 IU and 3000 IU) water for injections) using the supplied sterile Mix2Vial filter transfer device.
Slovenian: Prašek zdravila Helixate NexGen se lahko rekonstituira le s priloženim vehiklom (2,5 ml (za 250 i.e., 500 i.e. in 1000 i.e.)) ali 5 ml (za 2000 i.e. in 3000 i.e.) vode za injekcije).
English: If you forget to use Helixate NexGen
Slovenian: Če ste pozabili uporabiti zdravilo Helixate NexGen
English: While keeping the syringe plunger pressed, turn the system upside down and draw the solution into the syringe by pulling the plunger back slowly.
Slovenian: Medtem ko pritiskate bat injekcijske brizge, obrnite sistem na glavo in počasi vlecite bat injekcijske brizge, da se injekcijska brizga napolni z raztopino.
English: Gently swirl the product vial with the transparent adapter attached until the substance is fully dissolved.
Slovenian: Vialo z zdravilom s prozornim adapterjem nežno obračajte, dokler se prašek popolnoma ne raztopi.
English: Animal reproduction studies have not been conducted with Helixate NexGen.
Slovenian: Študije na živalih o vplivu zdravila Helixate NexGen na sposobnost razmnoževanja niso bile narejene.
English: Do not use Helixate NexGen
Slovenian: Ne uporabljajte zdravila Helixate NexGen
English: With one hand grasp the product-side of the Mix2Vial set and with the other hand grasp the solvent-side and unscrew counter clockwise the set carefully into two pieces.
Slovenian: Z eno roko primite komplet Mix2Vial na strani kjer je zdravilo, z drugo roko pa na strani kjer je vehikel in razstavite komplet na dva dela z odvijanjem v nasprotni smeri urinih kazalcev.
English: How Helixate NexGen is prepared for administration Use only the items that are provided with each package of this medicine.
Slovenian: Kako pripraviti zdravilo Helixate NexGen za uporabo Uporabite samo pribor, ki je priložen v vsakem pakiranju tega zdravila Če teh sestavnih delov ne morete uporabiti, se posvetujte z zdravnikom.
English: Helixate NexGen is provided as a powder and solvent for solution for injection and is a dry white to slightly yellow powder or cake.
Slovenian: Zdravilo Helixate NexGen je na voljo kot prašek (suh, bel do rahlo rumen prašek ali pogača) in vehikel za raztopino za injiciranje.
English: What Helixate NexGen looks like and content of the pack
Slovenian: Izgled zdravila Helixate NexGen in vsebina pakiranja
English: If a further dose needs to be administered, use a new syringe with product reconstituted as described above.
Slovenian: Če je potreben dodaten odmerek zdravila, uporabite novo injekcijsko brizgo z zdravilom,
English: The analysis of all recorded in vivo recoveries in previously treated patients demonstrated a mean rise of 2 % per IU/kg body weight for Helixate NexGen.
Slovenian: Iz analize podatkov o in vivo uporabnosti zdravila pri predhodno zdravljenih bolnikih z zdravilom Helixate NexGen so ugotovili, da 1 i.e. na kilogram telesne mase povprečno zviša aktivnost faktorja VIII za 2 %.
English: • the factor VIII level that is needed.
Slovenian: • želene raven faktorja VIII.
English: How to use Helixate NexGen
Slovenian: Kako uporabljati zdravilo Helixate NexGen
English: Allergic type hypersensitivity reactions are possible with Helixate NexGen.
Slovenian: Po uporabi zdravila Helixate NexGen se lahko pojavijo preobčutljivostne reakcije alergijskega tipa.
English: While the product vial is upright, connect the syringe to the Mix2Vial´s Luer Lock fitting by screwing clockwise.
Slovenian: Medtem ko je viala z zdravilom v pokončnem položaju, pritrdite injekcijsko brizgo na Mix2Vial Luer Lock s privijanjem v smeri urinih kazalcev.
English: Additional pharmacokinetic parameters for Helixate NexGen for bolus injection are: mean residence time [MRT (0-48)] of about 22 hours and clearance of about 160 mL/h.Mean baseline clearance for 14 adult patients undergoing major surgeries with continuous infusion are 188 mL/h corresponding to 3.0 mL/h/kg (range 1.6-4.6 mL/h/kg).
Slovenian: Povprečni začetni očistek pri 14-ih odraslih bolnikih pri katerih je bil narejen večji kirurški poseg in so dobili kontinuirano infuzijo, je 188 ml/h, kar ustreza 3,0 ml/h/kg (razpon 1,6 - 4,6 ml/h/kg).
English: Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with Helixate NexGen.
Slovenian: Pri bolnikih s hemofilijo A, zdravljenih s faktorjem VIII, vključno z zdravilom Helixate NexGen, lahko pride do nastanka nevtralizirajočih protiteles (zaviralcev).
English: The most serious side effects are hypersensitivity reactions or anaphylactic shock (rare side effect).
Slovenian: Najbolj resni neželeni učinki so preobčutljivostne reakcije ali anafilaktični šok (redek neželeni učinek).Če se pojavi alergijska ali anafilaktična reakcija, je treba takoj prenehati z injiciranjem/infundiranjem.
English: Helixate NexGen 250 IU contains (250 IU / 2.5 mL) = 100 IU octocog alfa per mL after reconstitution.
Slovenian: Zdravilo Helixate NexGen 250 i.e. vsebuje (250 i.e./ 2,5 ml) = 100 i.e. oktokoga alfa na ml po rekonstituciji
English: Helixate NexGen 2000 IU contains (2000 IU / 5 mL) = 400 IU octocog alfa per mL after reconstitution.
Slovenian: Zdravilo Helixate NexGen 2000 i.e. vsebuje (2000 i.e./ 5 ml) = 400 i.e. oktokoga alfa na ml po rekonstituciji
English: Helixate NexGen 250 IU powder and solvent for solution for injection Helixate NexGen 500 IU powder and solvent for solution for injection Helixate NexGen 1000 IU powder and solvent for solution for injection Helixate NexGen 2000 IU powder and solvent for solution for injection Helixate NexGen 3000 IU powder and solvent for solution for injection Recombinant coagulation factor VIII (octocog alfa)
Slovenian: Helixate NexGen 250 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 500 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 1000 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 2000 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 3000 i.e. prašek in vehikel za raztopino za injiciranje rekombinantni koagulacijski faktor VIII (oktokog alfa)
English: Helixate NexGen 3000 IU contains (3000 IU / 5 mL) = 600 IU octocog alfa per mL after reconstitution.
Slovenian: Zdravilo Helixate NexGen 3000 i.e. vsebuje (3000 i.e./ 5 ml) = 600 i.e. oktokoga alfa na ml po rekonstituciji
English: Helixate NexGen 500 IU contains (500 IU / 2.5 mL) = 200 IU octocog alfa per mL after reconstitution.
Slovenian: Zdravilo Helixate NexGen 500 i.e. vsebuje (500 i.e./ 2,5 ml) = 200 i.e. oktokoga alfa na ml po rekonstituciji
English: Helixate NexGen 250 IU powder and solvent for solution for injection Helixate NexGen 500 IU powder and solvent for solution for injection Helixate NexGen 1000 IU powder and solvent for solution for injection Helixate NexGen 2000 IU powder and solvent for solution for injection Helixate NexGen 3000 IU powder and solvent for solution for injection
Slovenian: Helixate NexGen 250 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 500 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 1000 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 2000 i.e. prašek in vehikel za raztopino za injiciranje Helixate NexGen 3000 i.e. prašek in vehikel za raztopino za injiciranje
English: Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you.
Slovenian: Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika ali farmacevta.
English: Helixate NexGen 1000 IU contains (1000 IU / 2.5 mL) = 400 IU octocog alfa per mL after reconstitution.
Slovenian: Zdravilo Helixate NexGen 1000 i.e. vsebuje (1000 i.e./ 2,5 ml) = 400 i.e. oktokoga alfa na ml po rekonstituciji
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL WITH 2.5 mL or 5 mL WATER FOR INJECTIONS
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA 1 viala s praškom za raztopino za injiciranje 1 viala, ki vsebuje 2,5 ml vode za injekcije 1 viala, ki vsebuje 5 ml vode za injekcije
English: • One mL Helixate NexGen 250 IU contains approximately 100 IU (250 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Slovenian: • 1 ml zdravila Helixate NexGen 250 i.e. vsebuje približno 100 i.e. (250 i.e./ 2,5 ml) rekombinantnega humanega koagulacijskega faktorja VIII (INN: oktokog alfa) po rekonstituciji z vodo za injekcije.
English: • One mL Helixate NexGen 500 IU contains approximately 200 IU (500 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Slovenian: • 1 ml zdravila Helixate NexGen 500 i.e. vsebuje približno 200 i.e. (500 i.e./ 2,5 ml) rekombinantnega humanega koagulacijskega faktorja VIII (INN: oktokog alfa) po rekonstituciji z vodo za injekcije.
English: What Helixate NexGen contains
Slovenian: Kaj vsebuje zdravilo Helixate NexGen
English: • One mL Helixate NexGen 3000 IU contains approximately 600 IU (3000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Slovenian: • 1 ml zdravila Helixate NexGen 3000 i.e. vsebuje približno 600 i.e. (3000 i.e./ 5 ml) rekombinantnega humanega koagulacijskega faktorja VIII (INN: oktokog alfa) po rekonstituciji z vodo za injekcije.
English: • One mL Helixate NexGen 1000 IU contains approximately 400 IU (1000 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Slovenian: • 1 ml zdravila Helixate NexGen 1000 i.e. vsebuje približno 400 i.e. (1000 i.e./ 2,5 ml) rekombinantnega humanega koagulacijskega faktorja VIII (INN: oktokog alfa) po rekonstituciji z vodo za injekcije.
English: • One mL Helixate NexGen 2000 IU contains approximately 400 IU (2000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Slovenian: • 1 ml zdravila Helixate NexGen 2000 i.e. vsebuje približno 400 i.e. (2000 i.e./ 5 ml) rekombinantnega humanega koagulacijskega faktorja VIII (INN: oktokog alfa) po rekonstituciji z vodo za injekcije.
English: Helixate NexGen 250 IU powder for solution for injection Helixate NexGen 500 IU powder for solution for injection Helixate NexGen 1000 IU powder for solution for injection Helixate NexGen 2000 IU powder for solution for injection Helixate NexGen 3000 IU powder for solution for injection
Slovenian: Helixate NexGen 250 i.e. prašek za raztopino za injiciranje Helixate NexGen 500 i.e. prašek za raztopino za injiciranje Helixate NexGen 1000 i.e. prašek za raztopino za injiciranje Helixate NexGen 2000 i.e. prašek za raztopino za injiciranje Helixate NexGen 3000 i.e. prašek za raztopino za injiciranje rekombinantni koagulacijski faktor VIII (oktokog alfa)
English: METHOD OF ADMINISTRATION For reconstitution of Helixate NexGen, see package leaflet.
Slovenian: Navodila za rekonstitucijo zdravila Helixate NexGen so navedena v navodilu za uporabo.
English: The vial contains a dry white to slightly yellow powder or cake, as well as water for injections to be used to reconstitute the contents of the vial.
Slovenian: FARMACEVTSKA OBLIKA prašek in vehikel za raztopino za injiciranje (sistem Bio-Set) Prašek: suh bel do rahlo rumen prašek ali pogača Vehikel: voda za injekcije, bistra, brezbarvna raztopina
English: Enyglid repaglinide
Slovenian: Enyglid repaglinid
English: It is available as tablets (0.5, 1 and 2 mg).
Slovenian: Na voljo je v obliki tablet (0,5, 1 in 2 mg).
English: The full EPAR for Enyglid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Enyglid je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Enyglid is taken before meals, normally up to 15 minutes before each main meal.
Slovenian: Zdravilo Enyglid se jemlje pred obroki, po navadi največ 15 minut pred vsakim glavnim obrokom.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Enyglid on 14 October 2009.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Enyglid, veljavno po vsej Evropski uniji, izdala 14. oktobra 2009.
English: What are the benefits and risks of Enyglid?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Enyglid?
English: This means that Enyglid is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu NovoNorm.
English: For more information about treatment with Enyglid, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Enyglid preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Enyglid.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: This is a summary of the European public assessment report (EPAR) for Enyglid.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Enyglid.
English: If patients are transferred from another diabetes medicine, the recommended starting dose is 1 mg.
Slovenian: Pri bolnikih, ki preidejo z drugega zdravila za sladkorno bolezen, je priporočeni začetni odmerek 1 mg.
English: Enyglid is a ‘generic medicine'.
Slovenian: Zdravilo Enyglid je „generično zdravilo“.
English: Because Enyglid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Enyglid generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The CHMP concluded that, in accordance with EU requirements, Enyglid has been shown to have comparable quality and to be bioequivalent to NovoNorm.
Slovenian: CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Enyglid primerljivo raven kakovosti kot zdravilo NovoNorm ter da mu je biološko enakovredno.
English: Enyglid is a diabetes medicine that contains the active substance repaglinide.
Slovenian: Enyglid je zdravilo za sladkorno bolezen, ki vsebuje zdravilno učinkovino repaglinid.
English: Because Enyglid is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, NovoNorm.
Slovenian: Ker je zdravilo Enyglid generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu NovoNorm.
English: The Committee recommended that Enyglid be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Enyglid izda dovoljenje za promet.
English: Other information about Enyglid
Slovenian: Druge informacije o zdravilu Enyglid
English: It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) is not adequately controlled by diet, weight reduction and exercise.
Slovenian: Uporablja se skupaj z dieto in telesno dejavnostjo za znižanje glukoze (sladkorja) v krvi pri bolnikih, pri katerih hiperglikemije (visoke koncentracije glukoze v krvi) ni mogoče nadzorovati z dieto, zmanjšanjem telesne mase in telesno dejavnostjo.
English: Why has Enyglid been approved?
Slovenian: Zakaj je bilo zdravilo Enyglid odobreno?
English: This dose may need to be increased after one or two weeks.
Slovenian: Priporočeni začetni odmerek je 0,5 mg, ki se po enem ali dveh tednih lahko poveča.
English: Enyglid may also be used with metformin (another diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Slovenian: Zdravilo Enyglid se lahko uporabi tudi z metforminom (drugim zdravilom za sladkorno bolezen) pri bolnikih s sladkorno boleznijo tipa 2, pri katerih samo z metforminom ni mogoče zadovoljivo nadzorovati ravni glukoze v krvi.
English: Enyglid is used in adults who have type 2 diabetes.
Slovenian: Zdravilo Enyglid se uporablja pri odraslih s sladkorno boleznijo tipa 2.
English: Enyglid helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Slovenian: Zdravilo Enyglid spodbuja trebušno slinavko, da med obroki tvori več insulina, zato se uporablja za nadzor sladkorne bolezni tipa 2.
English: How has Enyglid been studied?
Slovenian: Kako je bilo zdravilo Enyglid raziskano?
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom tudi pri bolnikih s sladkorno boleznijo tipa 2, pri katerih so ravni glukoze v krvi po navadi dobro nadzorovane z dieto, vendar doživljajo obdobja prehodne izgube nadzora.
English: What is Enyglid used for?
Slovenian: Za kaj se zdravilo Enyglid uporablja?
English: How is Enyglid used?
Slovenian: Kako se zdravilo Enyglid uporablja?
English: The marketing authorisation was renewed on 13 June 2005.
Slovenian: Dovoljenje za promet z zdravilom je bilo podaljšano 13. junija 2005.
English: These effects are mild and temporary.
Slovenian: Ti neželeni učinki so bili blagi in prehodni.
English: The standard dose is 15 mg per kilogram body weight once a day for the length of time determined by your veterinarian.
Slovenian: Običajen odmerek znaša 15 mg na kilogram telesne mase enkrat dnevno, ki ga je treba dajati tako dolgo, kot to določi veterinar.
English: Ibaflin is available as tablets (30, 150, 300 and 900 mg) and as oral gels (3 and 7.5%).
Slovenian: Na voljo je v obliki tablet (30, 150, 300 in 900 mg) in v obliki peroralnih gelov (3 % in 7,5 %).
English: This enzyme is only found in bacterial cells, and does not have a similar function in animal cells.
Slovenian: Ta encim je mogoče najti samo v celicah bakterij, v celicah živali pa nima podobne vloge.
English: For more information, see the Package Leaflet.
Slovenian: Za več informacij glejte
English: Other information about Ibaflin:
Slovenian: Druge informacije o zdravilu Ibaflin:
English: It works by blocking an enzyme called ‘DNA gyrase', which is important in allowing bacteria to make copies of their DNA.
Slovenian: Deluje tako, da zavre encim imenovan „DNA-giraza“, ki je pomemben zato, ker bakterijam omogoča, da izdelujejo kopije svoje DNA.
English: People who are hypersensitive (allergic) to quinolones should avoid any contact with Ibaflin.
Slovenian: Ljudje, ki so preobčutljivi za (alergični na) kinolone, se morajo izogibati vsakršnega stika z zdravilom Ibaflin.
English: Cats are treated using the 3% oral gel.
Slovenian: Za zdravljenje mačk se uporablja 3 % peroralni gel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ibaflin to Intervet International B.V. on 13 June 2000.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Ibaflin, veljavno po vsej Evropski uniji, odobrila družbi Intervet International B.V.
English: The use of ibafloxacin may result in an increase in the prevalence of resistant strains in the target species although this risk is likely to be less of a concern due to the treatment of individual animals with this product.
Slovenian: Uporaba ibafloksacina ima lahko za posledico povečanje pogostnosti pojavljanja odpornih sevov pri ciljnih vrstah, vendar pa je takšno tveganje zaradi tega, ker se s tem zdravilom zdravi le posamezne živali, manj zaskrbljujoče.
English: A strain which is resistant to one type of fluoroquinolone will also be resistant to other members of the class of fluoroquinolones.
Slovenian: Sev, ki je odporen na eno vrsto fluorokinolonov, bo odporen tudi na druge pripadnike iz skupine fluorokinolonov.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IBAFLIN EPAR summary for the public
Slovenian: IBAFLIN Povzetek EPAR za javnost
English: In these studies, the effects of Ibaflin were compared with those of other antibiotics (marbofloxacin, enrofloxacin or amoxicillin/clavulanic acid).
Slovenian: V teh študijah so učinke zdravila Ibaflin primerjali z učinki drugih antibiotikov (marbofloksacina, enrofloksacina ali amoksicilina/klavulanske kisline).
English: The dose and duration of treatment depend on the nature and severity of the infection, the weight and species of the animal being treated, and the animal's response to treatment.
Slovenian: Odmerek zdravila in trajanje zdravljenja sta odvisna od narave in resnosti okužbe, telesne mase in vrste živali, ki jo zdravimo, ter od tega,
English: By blocking DNA gyrase, ibafloxacin prevents the bacteria from making DNA and stops them making proteins and growing, resulting in their death.
Slovenian: Z zavrtjem DNA-giraze ibafloksacin bakterijam prepreči tvorbo DNA, s čimer pri njih zaustavi tvorbo beljakovin in rast, kar ima za posledico njihovo odmrtje.
English: However, the results were insufficient to support the use of Ibaflin in the treatment of urinary tract infections in cats.
Slovenian: Kljub temu pa rezultati niso zadostovali za podporo uporabe zdravila Ibaflin pri zdravljenju okužb sečil pri mačkah.
English: Why has Ibaflin been approved?
Slovenian: Zakaj je bilo zdravilo Ibaflin odobreno?
English: Ibaflin is used to treat the infections in dogs and cats:
Slovenian: Zdravilo Ibaflin se uporablja za zdravljenje okužb pri psih in mačkah: